John Houston, Arvinas CEO
Novartis lines up protein degrader deal with Pfizer-allied Arvinas
Novartis wants in on the work at Arvinas, one of the early leaders in the protein degrader field that has gotten into Phase 3 with partner Pfizer.
The Swiss pharma giant will pay $150 million upfront to license the mid-stage oral protein degrader ARV-766 and buy the preclinical AR-V7 program, the companies said Thursday morning. The biobucks are big at up to $1.01 billion, plus tiered royalties on ARV-766.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
